Oramed Phrmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced that the US patent for the technology “Protease inhibitor-Containing Compositions, Compositions Comprising Same, and Methods for Producing and using Same” has been allowed by the United States Patent and Trademark Office.
Nadav Kidron, CEO of Oramed Pharmaceuticals said, “This is an important patent in Oramed’s patent portfolio that protects a key aspect of our breakthrough technology. The protease inhibitors allow the insulin and other proteins to travel through the body intact”.
Oramed Pharmaceuticals Inc is a platform technology pioneer in the field of oran delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (POD) technology is based on over 30 years of research by scientists at the Jerusalem Hadassah Medical Center.
Oramed is seeking to revolutionarize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule. The Company completed multiple Phase II clinical trials under n investigational New Drug application with the US Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule.